Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexamethasone sodium phosphate + povidone-iodine + ropivacaine is a **combination injection kit product** reported to be marketed under the brand names **ROPIDEX** and **DEXOPIN** and distributed by **Asclemed USA**. The product combines three small-molecule components with distinct roles: dexamethasone sodium phosphate, a water-soluble corticosteroid prodrug of dexamethasone that exerts anti-inflammatory and immunosuppressive effects via glucocorticoid receptor signaling; ropivacaine, an amino amide local anesthetic that blocks voltage-gated sodium channels to produce regional analgesia/anesthesia; and povidone-iodine, a topical antiseptic iodophor that releases iodine and provides broad antimicrobial activity. Based on the supplied context, the kit appears intended for injection-related procedural use rather than representing a novel molecular entity. A notable safety consideration from the literature is that admixture of ropivacaine with dexamethasone sodium phosphate has been reported to cause crystallization, which may be relevant for certain injection applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone sodium phosphate + povidone-iodine + ropivacaine.